We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.629 | 1.62 | 1.638 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.98M | -0.0035 | -4.69 | 18.73M |
From Apr 2019 to Apr 2024
TIDMHEMO
RNS Number : 7699S
Hemogenyx Pharmaceuticals PLC
27 June 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Result of AGM
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR & Co-Founder Sir Marc Feldmann, Executive Chairman Optiva Securities Ltd Tel: +44 (0)20 3137 1902 Christian Dennis Shard Capital Partners LLP Tel: +44 (0)20 7186 9950 Damon Heath, Erik Woolgar Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com Relations) Paul McManus Mob: +44 (0)7980 541 893 US Media enquiries Lowell Goodman Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGSEAFSWFASEDM
(END) Dow Jones Newswires
June 27, 2018 06:39 ET (10:39 GMT)
1 Year Hemogenyx Pharmaceuticals Chart |
1 Month Hemogenyx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
